Anixa Biosciences (ANIX) Research & Development (2010 - 2026)
Anixa Biosciences (ANIX) posted Research & Development of $1.33 million for fiscal Q3 2026 (quarter ended Jul 31, 2026), up 25.7% from $1.06 million a year earlier and up 5.4% from the prior quarter.
Anixa Biosciences (ANIX) Research & Development (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jul 31, 2026, Research & Development at Anixa Biosciences was $4.78 million, down 11.5% year-over-year; for FY2025 (ended Oct 31, 2025), it was $5.07 million, down 20.7% from FY2024.
- Annual Research & Development shows a five-year compound annual growth rate of 3.0% (FY2020 to FY2025).
- In prior fiscal years, Anixa Biosciences' Research & Development was $6.4 million in FY2024 (+34.1%), $4.77 million in FY2023 (-28.9%), $6.7 million in FY2022 (+8.3%) and $6.19 million in FY2021 (+41.3%).
- The fiscal Q3 2026 figure stands as the highest quarterly Research & Development since fiscal Q1 2025.
- On a year-over-year basis, Research & Development increased in two of the last seven quarters, with an average decline of 8.6%.
- The strongest year-over-year quarter for Research & Development in the past five years was fiscal Q4 2021, with growth of 433.0%; the weakest was fiscal Q3 2025, with a decline of 45.2%.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Anixa Biosciences | 96.15 Mn | 81.01 Mn | - | 1.33 Mn |
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 1.33 Mn |
| Apr 30, 2026 | 1.26 Mn |
| Oct 31, 2025 | 1.14 Mn |
| Jul 31, 2025 | 1.06 Mn |
| Apr 30, 2025 | 1.32 Mn |
| Jan 31, 2025 | 1.55 Mn |
| Oct 31, 2024 | 1.48 Mn |
| Jul 31, 2024 | 1.93 Mn |
| Apr 30, 2024 | 1.65 Mn |
| Jan 31, 2024 | 1.35 Mn |
| Oct 31, 2023 | 1.62 Mn |
| Jul 31, 2023 | 1.09 Mn |
| Apr 30, 2023 | 998,000.00 |
| Jan 31, 2023 | 1.07 Mn |
| Oct 31, 2022 | 1.69 Mn |
| Jul 31, 2022 | 1.45 Mn |
| Apr 30, 2022 | 1.74 Mn |
| Jan 31, 2022 | 1.84 Mn |
| Oct 31, 2021 | 2.17 Mn |
| Jul 31, 2021 | 2.17 Mn |
Anixa Biosciences Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ANIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ANIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ANIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();